Institut Curie Announces formation of Honing Biosciences for the Development of Cell Therapies in Cancer and Chronic Diseases

 Institut Curie Announces formation of Honing Biosciences for the Development of Cell Therapies in Cancer and Chronic Diseases

Institut Curie Announces formation of Honing Biosciences for the Development of Cell Therapies in Cancer and Chronic Diseases

Shots:

  • Honing Biosciences will use CellTune molecular technology, that will initially emphasize on cancer immunotherapies particularly the CAR-T cells to target cancer cells
  • The focus on this launch is to provide long-term care for cancer patients using a single injection of therapeutic cells, with the development of safe, effective and affordable approaches
  • CellTune molecular technology monitors the dynamic distribution of proteins in cell-medicaments that will further help in developing new class of cell therapies

Click here to read full press release/ article | Ref: Institut Curie | Image: Business wire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post